Hikma Pharmaceuticals (GB ... this continuity in auditing services a point of stability for the company’s financial oversight. TipRanks is the most comprehensive data set of sell side analysts ...

Analyst Christian Glennie from Stifel Nicolaus reiterated a Buy rating on Hikma Pharmaceuticals (HIK – Research Report) and keeping the ...

Shares of Hikma Pharmaceuticals PLC HIK inched up 0.33% to £18.37 Monday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.65% to ...

Shares of Hikma Pharmaceuticals PLC HIK rallied 1.64% to £18.01 Thursday, on what proved to be an all-around poor trading ...

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday said it is on track to deliver "another strong performance" following trading to date, and reiterates its full-year revenue expectations.

London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma ... and the UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), Hikma does not undertake ...

Companies like Aprecia Pharmaceuticals Co, Austedo, Hikma Pharmaceuticals ... initiatives aimed at optimizing market share and financial performance. By harnessing these strategic recommendations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The company also reiterated guidance for its Branded business of revenue in the high-single digits, or 6% to 8% higher year-on-year, with a core operating margin around 25%. Its Generics business is ...